+关注
Applemh1928
暂无个人介绍
IP属地：未知
11
关注
5
粉丝
0
主题
0
勋章
主贴
热门
Applemh1928
2021-12-08
[Miser] [Miser]
Pfizer, BioNTech say third dose neutralizes Omicron variant
Applemh1928
2021-10-25
[财迷]
Supply Chain Chaos: 2 Stocks Set to Crush the Market in 2022 (and Beyond)
Applemh1928
2021-10-04
[财迷] [财迷] [财迷]
Is This The End Of The World As We Know It?
Applemh1928
2021-09-13
[财迷] [财迷] [财迷]
抱歉，原内容已删除
Applemh1928
2021-08-17
[真香] [真香]
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4089370506564720,"uuid":"4089370506564720","gmtCreate":1626269120567,"gmtModify":1628043335779,"name":"Applemh1928","pinyin":"applemh1928","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":11,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.12","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":602305176,"gmtCreate":1638967612669,"gmtModify":1638967612800,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[Miser] [Miser] ","listText":"[Miser] [Miser] ","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602305176","repostId":"1177589023","repostType":2,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856633838,"gmtCreate":1635172353046,"gmtModify":1635172353624,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] ","listText":"[财迷] ","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856633838","repostId":"2178950426","repostType":4,"repost":{"id":"2178950426","pubTimestamp":1635170520,"share":"https://www.laohu8.com/m/news/2178950426?lang=&edition=full","pubTime":"2021-10-25 22:02","market":"us","language":"en","title":"Supply Chain Chaos: 2 Stocks Set to Crush the Market in 2022 (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2178950426","media":"Motley Fool","summary":"These companies have tailwinds working in their favor.","content":"<p>Last year, pandemic-driven business closures weakened global supply chains, reducing the availability of raw materials and other goods. As lockdowns were lifted, the spike in consumer demand put more pressure on an already strained system. And in August, a record 4.3 million Americans quit their jobs, adding labor shortages to the list of headwinds.</p>\n<p>This chaos is already impacting consumers, who are finding it more difficult to buy everything from automobiles and electronics to household products and medicine. Unfortunately, experts believe it will be at least six months (and maybe more than a year) before supply chains normalize, meaning industries like construction, manufacturing, and retail are likely to face significant headwinds for the foreseeable future.</p>\n<p>However, this difficult situation may actually be a tailwind for companies like <b>Airbnb</b> (NASDAQ:ABNB) and <b>Coupa Software</b> (NASDAQ:COUP). Here's why both of these stocks could crush the market in 2022 (and beyond).</p>\n<h2>Airbnb: A disruptive business model</h2>\n<p>Airbnb is disrupting the travel and tourism industry. Its platform crowdsources lodgings from over 4 million hosts worldwide, helping guests find a place to stay in over 100,000 cities. More importantly, Airbnb offers a far greater selection, both in terms of location and real estate, than traditional hotel chains.</p>\n<p>Guests can book a private cottage by the coast, a rustic farmhouse in a small town, or a trendy apartment in the heart of a big city. Airbnb also lists a variety of unique lodgings, such as a treehouse in the rainforest or a castle on the English countryside, providing a once-in-a-lifetime experience for travelers.</p>\n<p>That advantage has helped Airbnb recover more quickly from the pandemic. Through the first half of the year, the company's revenue skyrocketed 89%. Meanwhile, <b>Hyatt</b> and <b>Hilton</b> -- the two most valuable hotel brands in the world, according to Brand Finance -- both posted revenue declines of 11% over the same period. Airbnb also saw its gross booking value rise 320% to $13.4 billion, implying strong revenue growth in the coming quarters.</p>\n<p>Looking ahead, supply chain chaos and labor shortages could further reinforce Airbnb's advantage. Hilton CEO Chris Nassetta recently said difficulty staffing hotels is \"probably the single biggest issue\" that the company faces. And Hilton isn't alone. <b>Marriott</b> currently has over 10,000 empty positions across 600 hotels, which may translate into a poor experience for guests on its properties. Additionally, any new construction or renovation projects will likely take longer to complete in the current environment, limiting any near-term expansion plans.</p>\n<p>Meanwhile, Airbnb can onboard new hosts and expand its inventory in a matter of minutes, while incurring minimal costs. That means it can adapt to changes in consumer demand much more nimbly than its rivals. Of course, this is true even without supply chain challenges, but the current environment makes it even more relevant.</p>\n<p>Ultimately, these tailwinds should help Airbnb gain market share. That's why this growth stock is set to crush the market in 2022 (and beyond).</p>\n<h2>Coupa Software: A better supply chain solution</h2>\n<p>Coupa specializes in business spend management (BSM). Its platform connects its clients with over 7 million global suppliers, helping them purchase the goods and services they need to run their businesses. At the same time, Coupa's BSM tools help companies build more robust supply chains and realize cost savings through strategic procurement.</p>\n<p>For example, clients benefit from pre-negotiated discounts with suppliers -- a result of Coupa's scale -- creating a network effect that should strengthen over time. In other words, each new buyer on the platform creates value for every supplier, and vice versa. Coupa also orchestrates group sourcing events, allowing businesses to pool their collective buying power to negotiate better prices.</p>\n<p>Building on that, all of these transactions create data, and Coupa leans on artificial intelligence to make sense of that information, surfacing insights that help clients capitalize on savings opportunities and avoid risky suppliers. In fact, Coupa is the only BSM platform that offers real-time prescriptive insights, giving the company an edge over its rivals.</p>\n<p>Coupa further differentiates itself with Coupa Pay, a deeply integrated payments platform that streamlines the procurement process. Again, no other player in the industry has a comparable solution. These advantages have translated into strong financial results.</p>\n<p>In the most recent quarter, Coupa's trailing-12-month revenue surged 40% to $643 million, and while the company is still unprofitable on a GAAP basis, free cash flow hit $101 million, up 37%. Coupa also launched an App Marketplace, allowing clients to sync data with analytics tools like <b>Microsoft</b> Power BI and human resources software like <b><a href=\"https://laohu8.com/S/WDAY\">Workday</a></b>. This move further extends the functionality of its BSM platform, strengthening the value proposition for potential and existing customers.</p>\n<p>Going forward, Coupa should see an uptick in demand as supply chain bottlenecks continue to weigh on enterprises around the world. And with an addressable market at $94 billion, this tech company certainly has plenty of room to grow. That's why Coupa is set to crush the market in 2022 (and beyond).</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supply Chain Chaos: 2 Stocks Set to Crush the Market in 2022 (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupply Chain Chaos: 2 Stocks Set to Crush the Market in 2022 (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-25 22:02 GMT+8 <a href=https://www.fool.com/investing/2021/10/25/2-stocks-set-to-crush-the-market-in-2022-airbnb/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last year, pandemic-driven business closures weakened global supply chains, reducing the availability of raw materials and other goods. As lockdowns were lifted, the spike in consumer demand put more ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/25/2-stocks-set-to-crush-the-market-in-2022-airbnb/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUP":"Coupa Software Inc","ABNB":"爱彼迎"},"source_url":"https://www.fool.com/investing/2021/10/25/2-stocks-set-to-crush-the-market-in-2022-airbnb/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178950426","content_text":"Last year, pandemic-driven business closures weakened global supply chains, reducing the availability of raw materials and other goods. As lockdowns were lifted, the spike in consumer demand put more pressure on an already strained system. And in August, a record 4.3 million Americans quit their jobs, adding labor shortages to the list of headwinds.\nThis chaos is already impacting consumers, who are finding it more difficult to buy everything from automobiles and electronics to household products and medicine. Unfortunately, experts believe it will be at least six months (and maybe more than a year) before supply chains normalize, meaning industries like construction, manufacturing, and retail are likely to face significant headwinds for the foreseeable future.\nHowever, this difficult situation may actually be a tailwind for companies like Airbnb (NASDAQ:ABNB) and Coupa Software (NASDAQ:COUP). Here's why both of these stocks could crush the market in 2022 (and beyond).\nAirbnb: A disruptive business model\nAirbnb is disrupting the travel and tourism industry. Its platform crowdsources lodgings from over 4 million hosts worldwide, helping guests find a place to stay in over 100,000 cities. More importantly, Airbnb offers a far greater selection, both in terms of location and real estate, than traditional hotel chains.\nGuests can book a private cottage by the coast, a rustic farmhouse in a small town, or a trendy apartment in the heart of a big city. Airbnb also lists a variety of unique lodgings, such as a treehouse in the rainforest or a castle on the English countryside, providing a once-in-a-lifetime experience for travelers.\nThat advantage has helped Airbnb recover more quickly from the pandemic. Through the first half of the year, the company's revenue skyrocketed 89%. Meanwhile, Hyatt and Hilton -- the two most valuable hotel brands in the world, according to Brand Finance -- both posted revenue declines of 11% over the same period. Airbnb also saw its gross booking value rise 320% to $13.4 billion, implying strong revenue growth in the coming quarters.\nLooking ahead, supply chain chaos and labor shortages could further reinforce Airbnb's advantage. Hilton CEO Chris Nassetta recently said difficulty staffing hotels is \"probably the single biggest issue\" that the company faces. And Hilton isn't alone. Marriott currently has over 10,000 empty positions across 600 hotels, which may translate into a poor experience for guests on its properties. Additionally, any new construction or renovation projects will likely take longer to complete in the current environment, limiting any near-term expansion plans.\nMeanwhile, Airbnb can onboard new hosts and expand its inventory in a matter of minutes, while incurring minimal costs. That means it can adapt to changes in consumer demand much more nimbly than its rivals. Of course, this is true even without supply chain challenges, but the current environment makes it even more relevant.\nUltimately, these tailwinds should help Airbnb gain market share. That's why this growth stock is set to crush the market in 2022 (and beyond).\nCoupa Software: A better supply chain solution\nCoupa specializes in business spend management (BSM). Its platform connects its clients with over 7 million global suppliers, helping them purchase the goods and services they need to run their businesses. At the same time, Coupa's BSM tools help companies build more robust supply chains and realize cost savings through strategic procurement.\nFor example, clients benefit from pre-negotiated discounts with suppliers -- a result of Coupa's scale -- creating a network effect that should strengthen over time. In other words, each new buyer on the platform creates value for every supplier, and vice versa. Coupa also orchestrates group sourcing events, allowing businesses to pool their collective buying power to negotiate better prices.\nBuilding on that, all of these transactions create data, and Coupa leans on artificial intelligence to make sense of that information, surfacing insights that help clients capitalize on savings opportunities and avoid risky suppliers. In fact, Coupa is the only BSM platform that offers real-time prescriptive insights, giving the company an edge over its rivals.\nCoupa further differentiates itself with Coupa Pay, a deeply integrated payments platform that streamlines the procurement process. Again, no other player in the industry has a comparable solution. These advantages have translated into strong financial results.\nIn the most recent quarter, Coupa's trailing-12-month revenue surged 40% to $643 million, and while the company is still unprofitable on a GAAP basis, free cash flow hit $101 million, up 37%. Coupa also launched an App Marketplace, allowing clients to sync data with analytics tools like Microsoft Power BI and human resources software like Workday. This move further extends the functionality of its BSM platform, strengthening the value proposition for potential and existing customers.\nGoing forward, Coupa should see an uptick in demand as supply chain bottlenecks continue to weigh on enterprises around the world. And with an addressable market at $94 billion, this tech company certainly has plenty of room to grow. That's why Coupa is set to crush the market in 2022 (and beyond).","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820344033,"gmtCreate":1633355883839,"gmtModify":1633355985746,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] [财迷] [财迷] ","listText":"[财迷] [财迷] [财迷] ","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820344033","repostId":"1139003361","repostType":4,"repost":{"id":"1139003361","pubTimestamp":1633342670,"share":"https://www.laohu8.com/m/news/1139003361?lang=&edition=full","pubTime":"2021-10-04 18:17","market":"us","language":"en","title":"Is This The End Of The World As We Know It?","url":"https://stock-news.laohu8.com/highlight/detail?id=1139003361","media":"seekingalpha","summary":"Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upo","content":"<p>Summary</p>\n<ul>\n <li>Too many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.</li>\n <li>The market has struck an important support region.</li>\n <li>As long as this support holds, I am looking next to the 4900-5000SPX region.</li>\n <li>This idea was discussed in more depth with members of my private investing community, The Market Pinball Wizard.</li>\n</ul>\n<p>I have to tell you that I get the biggest chuckle out of the comments I read from people on Seeking Alpha.</p>\n<p>Recently, I read yet another bearish article on the market, and I found a comment which I can appropriately summarize thusly:</p>\n<blockquote>\n <i>\"I love your articles. They are so well written, such great charts, such great analysis, but why has the crash not happened yet?\"</i>\n</blockquote>\n<p>Then, I saw the following response:</p>\n<blockquote>\n <i>\"The crash hasn't happened because the market is in denial. If it weren't for that, the analysis would be spot on. The market simply refuses to acknowledge reality. It really should talk to a psychologist.\"</i>\n</blockquote>\n<p>Folks, the point I am trying to make by highlighting these comments is that we cannot make the market bend to what we may believe to be “reality.” We need to look at the market objectively in order to make our assessments about the future direction of the market. Simply calling the market a name or thinking it has been displaced from reality will never help your investment account.</p>\n<p>Yet, most people have a bias as to what they think must happen in the market, and apply that bias to their investment account, with many even posting comments based upon that bias. The two comments above are perfect examples.</p>\n<p>The main problem is that many do not have the appropriate objective tools with which to ascertain market direction. Rather, many view the market fundamentals as providing the clues to market direction. But, unfortunately, that is not how the market works, and it has seriously led people astray, with so many fighting this rally off the March 2020 lows.</p>\n<p>I have explained this in past articles such as this one, but the main point is that sentiment is what drives the market and places the spin on how the public views any of the fundamentals. If the market is in a positive sentiment trend, then negative fundamentals will be ignored, and vice versa. We have all seen markets rally on bad news and wonder “how the heck is this possible?” I often post this picture from Jim Cramer’s show as the perfect example of when this happens:</p>\n<p>With our objective analysis, not only did we catch the bottom last year at 2200SPX, I even said before we bottomed that we will likely see a strong rally to at least the 4000SPX region, with my ideal target being the 6000SPX region. Now, if you remember the emotional environment at the time, I am sure you can understand why so many looked at me like I was crazy. But, it was clearly not the first call I have made that has elicited such a response. In fact, it was not even the 20th.</p>\n<p>I even saw one comment this past week that said:</p>\n<blockquote>\n <i>“Avi is right more often than I would like to admit.”</i>\n</blockquote>\n<p>The question I always ask is why do so many people fight what I am trying to teach? Well, there are a number of reasons.</p>\n<p>First, in order to accept what I am saying about the market, you have to unlearn all the things you have learned all these years about what drives the market.</p>\n<p>And, I can tell you that those that are able not only find it liberating, but also find it much more profitable:</p>\n<blockquote>\n <i>“Avi's service is a game changer! I started reading his public articles more than four years ago. I should have subscribed sooner. Through his service, I have learned to ignore the mass market miss-information. This has vastly improved my investing success. Put in the time to learn from the master. You won't believe the success you will achieve once you have gained this new perspective. Avi and his team are fantastic!”</i>\n</blockquote>\n<blockquote>\n <i>“I have heard and read about Avi Gilburt and The Market Pinball Wizard for several years prior to actually joining. Like others here I subscribed to several authors including Avi, and would read the public articles. At first, I like probably many others, was skeptical of the service and what was put forth . . . I had to \"unlearn what I had learned\", tune out the news and TV pundits and focus on purely the market. This was not easy as I usually thought the market was hooked at the hip of the economy in real time. Whether you are a novice investor and are just looking for \"macro\" ideas and guidance as to what's in front of you or a seasoned pro, this service, in my opinion, is invaluable! . . . This service is a investment game changer for sure!!”</i>\n</blockquote>\n<p>Second, it requires you to understand that the market is driven by emotion and not by logic. In order to do so, many have to give up viewing the market logically. Yet, most people cannot accept the market action unless they believe they know the reason as to why the market moved.</p>\n<p>What they don’t understand is that reasons are completely useless. They are only offered by the media and pundits after the fact to attempt to explain a move that already happened. And, there are many times they cannot even find a reason as to why a market move happened, which leads to some of the funniest headlines you will see, assuming you are paying attention.</p>\n<p>Consider what was written by Professor Hernan Cortes Douglas, former Luksic Scholar at Harvard University, former Deputy Research Administrator at the World Bank, and former Senior Economist at the IMF, regarding those engaged in “fundamental” analysis for predictive purposes regarding the stock market:</p>\n<blockquote>\n <i>The historical data say that they cannot succeed; financial markets never collapse when things look bad. In fact, quite the contrary is true. Before contractions begin, macroeconomic flows always look fine. That is why the vast majority of economists always proclaim the economy to be in excellent health just before it swoons. Despite these failures, indeed despite repeating almost precisely those failures, economists have continued to pore over the same macroeconomic fundamentals for clues to the future. If the conventional macroeconomic approach is useless even in retrospect, if it cannot explain or understand an outcome when we know what it is, has it a prayer of doing so when the goal is assessing the future?</i>\n</blockquote>\n<p>And, the exact opposite is true. Did not the economic world consider us in a recession during the entire rally from 2200 to 4000?</p>\n<p>As we came into 2021 (with the market starting the year out at 3750SPX), I outlined to those willing to listen that I was expecting at least a 20% rally, with at least the 4600SPX as my target for 2021. That means I was looking for a rally of at least 850 points. Thus far, we have clearly exceeded my 20% minimum rally expectation, and the market has rallied 800 points and come within 50 points of the 4600SPX target I set for this year.</p>\n<p>Many months ago I also noted that I think we can get a 200-300 point pullback from the 4440-4600SPX region before we are ready to rally through 4600SPX. And, as we can see now, the market is again obliging our expectations.</p>\n<p>The funny thing is that I actually got chided recently by another commenter that acknowledged that we are getting the 200-300 point pullback I was expecting, but faulted me for the market topping at 4550SPX and not 4600SPX. I just shook my head in amazement when I read that comment. I caught 800 of the 850 points I called for earlier this year, and even called for this 200-300 point decline. But, sadly, I was simply not perfect in his myopic view. The real truth is that I noted that the 200-300 point decline can begin from the 4440-4600SPX target zone. But, who cares about the truth. (smile)</p>\n<p>Again, it is just so hard for people to let go of what they believe about the market. Sadly, this is the nature of far too many market participants, as so many still fight what I am trying to outline and teach about the market. But, rest assured, I still think we have plenty of time to be able to get to that 4600SPX mark before the end of the year, and potentially even exceed it.</p>\n<p>For many months, I have been outlining a major market pivot to the members of my The Market Pinball Wizard analysis service between 4095-4270SPX. That is the major support in the market at this time. And, I noted earlier this year to our members that once the market exceeds that pivot, it will rally into the 4440-4600SPX region, and then come back to test that market pivot from above. As long as the market holds that support region, I am looking for a signal that we have begun our next rally to our next major target in the 4900-5000SPX region.</p>\n<p>At the end of the week this past week, the futures market struck the top of this support region at the equivalent of the 4270SPX on the nose, and Friday we experienced a very strong rally off that support. Yet, I need to see a 5-wave structure off the low to provide us with our initial signal that the rally to 4900+ has begun in earnest.</p>\n<p>If we do not see that 5-wave structure complete early in the coming week, and instead, we break down below 4320SPX, then it likely means that this current pullback has not yet completed, and we will likely drop towards the 4200-4220SPX region, and ultimately point us down towards the 4165SPX region.</p>\n<p>So, I believe the coming week will provide us clues as to whether we have hit our bottom at the top end of our support region, and have begun the next rally to 4900+, or if we have deeper to go into our support region before that next rally begins in earnest.</p>\n<p>Hey, who knows? I could always be wrong. But, when the two top trending articles on Seeking Alpha this weekend were about an impending bear market and the most dangerous market ever, well, the boat is starting to feel a bit weighty on one side. Have a good week all.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is This The End Of The World As We Know It?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs This The End Of The World As We Know It?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 18:17 GMT+8 <a href=https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.\nThe market has struck an important support region.\nAs long as this ...</p>\n\n<a href=\"https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1139003361","content_text":"Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.\nThe market has struck an important support region.\nAs long as this support holds, I am looking next to the 4900-5000SPX region.\nThis idea was discussed in more depth with members of my private investing community, The Market Pinball Wizard.\n\nI have to tell you that I get the biggest chuckle out of the comments I read from people on Seeking Alpha.\nRecently, I read yet another bearish article on the market, and I found a comment which I can appropriately summarize thusly:\n\n\"I love your articles. They are so well written, such great charts, such great analysis, but why has the crash not happened yet?\"\n\nThen, I saw the following response:\n\n\"The crash hasn't happened because the market is in denial. If it weren't for that, the analysis would be spot on. The market simply refuses to acknowledge reality. It really should talk to a psychologist.\"\n\nFolks, the point I am trying to make by highlighting these comments is that we cannot make the market bend to what we may believe to be “reality.” We need to look at the market objectively in order to make our assessments about the future direction of the market. Simply calling the market a name or thinking it has been displaced from reality will never help your investment account.\nYet, most people have a bias as to what they think must happen in the market, and apply that bias to their investment account, with many even posting comments based upon that bias. The two comments above are perfect examples.\nThe main problem is that many do not have the appropriate objective tools with which to ascertain market direction. Rather, many view the market fundamentals as providing the clues to market direction. But, unfortunately, that is not how the market works, and it has seriously led people astray, with so many fighting this rally off the March 2020 lows.\nI have explained this in past articles such as this one, but the main point is that sentiment is what drives the market and places the spin on how the public views any of the fundamentals. If the market is in a positive sentiment trend, then negative fundamentals will be ignored, and vice versa. We have all seen markets rally on bad news and wonder “how the heck is this possible?” I often post this picture from Jim Cramer’s show as the perfect example of when this happens:\nWith our objective analysis, not only did we catch the bottom last year at 2200SPX, I even said before we bottomed that we will likely see a strong rally to at least the 4000SPX region, with my ideal target being the 6000SPX region. Now, if you remember the emotional environment at the time, I am sure you can understand why so many looked at me like I was crazy. But, it was clearly not the first call I have made that has elicited such a response. In fact, it was not even the 20th.\nI even saw one comment this past week that said:\n\n“Avi is right more often than I would like to admit.”\n\nThe question I always ask is why do so many people fight what I am trying to teach? Well, there are a number of reasons.\nFirst, in order to accept what I am saying about the market, you have to unlearn all the things you have learned all these years about what drives the market.\nAnd, I can tell you that those that are able not only find it liberating, but also find it much more profitable:\n\n“Avi's service is a game changer! I started reading his public articles more than four years ago. I should have subscribed sooner. Through his service, I have learned to ignore the mass market miss-information. This has vastly improved my investing success. Put in the time to learn from the master. You won't believe the success you will achieve once you have gained this new perspective. Avi and his team are fantastic!”\n\n\n“I have heard and read about Avi Gilburt and The Market Pinball Wizard for several years prior to actually joining. Like others here I subscribed to several authors including Avi, and would read the public articles. At first, I like probably many others, was skeptical of the service and what was put forth . . . I had to \"unlearn what I had learned\", tune out the news and TV pundits and focus on purely the market. This was not easy as I usually thought the market was hooked at the hip of the economy in real time. Whether you are a novice investor and are just looking for \"macro\" ideas and guidance as to what's in front of you or a seasoned pro, this service, in my opinion, is invaluable! . . . This service is a investment game changer for sure!!”\n\nSecond, it requires you to understand that the market is driven by emotion and not by logic. In order to do so, many have to give up viewing the market logically. Yet, most people cannot accept the market action unless they believe they know the reason as to why the market moved.\nWhat they don’t understand is that reasons are completely useless. They are only offered by the media and pundits after the fact to attempt to explain a move that already happened. And, there are many times they cannot even find a reason as to why a market move happened, which leads to some of the funniest headlines you will see, assuming you are paying attention.\nConsider what was written by Professor Hernan Cortes Douglas, former Luksic Scholar at Harvard University, former Deputy Research Administrator at the World Bank, and former Senior Economist at the IMF, regarding those engaged in “fundamental” analysis for predictive purposes regarding the stock market:\n\nThe historical data say that they cannot succeed; financial markets never collapse when things look bad. In fact, quite the contrary is true. Before contractions begin, macroeconomic flows always look fine. That is why the vast majority of economists always proclaim the economy to be in excellent health just before it swoons. Despite these failures, indeed despite repeating almost precisely those failures, economists have continued to pore over the same macroeconomic fundamentals for clues to the future. If the conventional macroeconomic approach is useless even in retrospect, if it cannot explain or understand an outcome when we know what it is, has it a prayer of doing so when the goal is assessing the future?\n\nAnd, the exact opposite is true. Did not the economic world consider us in a recession during the entire rally from 2200 to 4000?\nAs we came into 2021 (with the market starting the year out at 3750SPX), I outlined to those willing to listen that I was expecting at least a 20% rally, with at least the 4600SPX as my target for 2021. That means I was looking for a rally of at least 850 points. Thus far, we have clearly exceeded my 20% minimum rally expectation, and the market has rallied 800 points and come within 50 points of the 4600SPX target I set for this year.\nMany months ago I also noted that I think we can get a 200-300 point pullback from the 4440-4600SPX region before we are ready to rally through 4600SPX. And, as we can see now, the market is again obliging our expectations.\nThe funny thing is that I actually got chided recently by another commenter that acknowledged that we are getting the 200-300 point pullback I was expecting, but faulted me for the market topping at 4550SPX and not 4600SPX. I just shook my head in amazement when I read that comment. I caught 800 of the 850 points I called for earlier this year, and even called for this 200-300 point decline. But, sadly, I was simply not perfect in his myopic view. The real truth is that I noted that the 200-300 point decline can begin from the 4440-4600SPX target zone. But, who cares about the truth. (smile)\nAgain, it is just so hard for people to let go of what they believe about the market. Sadly, this is the nature of far too many market participants, as so many still fight what I am trying to outline and teach about the market. But, rest assured, I still think we have plenty of time to be able to get to that 4600SPX mark before the end of the year, and potentially even exceed it.\nFor many months, I have been outlining a major market pivot to the members of my The Market Pinball Wizard analysis service between 4095-4270SPX. That is the major support in the market at this time. And, I noted earlier this year to our members that once the market exceeds that pivot, it will rally into the 4440-4600SPX region, and then come back to test that market pivot from above. As long as the market holds that support region, I am looking for a signal that we have begun our next rally to our next major target in the 4900-5000SPX region.\nAt the end of the week this past week, the futures market struck the top of this support region at the equivalent of the 4270SPX on the nose, and Friday we experienced a very strong rally off that support. Yet, I need to see a 5-wave structure off the low to provide us with our initial signal that the rally to 4900+ has begun in earnest.\nIf we do not see that 5-wave structure complete early in the coming week, and instead, we break down below 4320SPX, then it likely means that this current pullback has not yet completed, and we will likely drop towards the 4200-4220SPX region, and ultimately point us down towards the 4165SPX region.\nSo, I believe the coming week will provide us clues as to whether we have hit our bottom at the top end of our support region, and have begun the next rally to 4900+, or if we have deeper to go into our support region before that next rally begins in earnest.\nHey, who knows? I could always be wrong. But, when the two top trending articles on Seeking Alpha this weekend were about an impending bear market and the most dangerous market ever, well, the boat is starting to feel a bit weighty on one side. Have a good week all.","news_type":1},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886005693,"gmtCreate":1631535569712,"gmtModify":1631890655211,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] [财迷] [财迷] ","listText":"[财迷] [财迷] [财迷] ","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886005693","repostId":"1129341543","repostType":4,"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":833016613,"gmtCreate":1629188980932,"gmtModify":1631893057089,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[真香] [真香] ","listText":"[真香] [真香] ","text":"[真香] [真香]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/833016613","repostId":"1192890684","repostType":2,"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":602305176,"gmtCreate":1638967612669,"gmtModify":1638967612800,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[Miser] [Miser] ","listText":"[Miser] [Miser] ","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602305176","repostId":"1177589023","repostType":2,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856633838,"gmtCreate":1635172353046,"gmtModify":1635172353624,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] ","listText":"[财迷] ","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856633838","repostId":"2178950426","repostType":4,"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820344033,"gmtCreate":1633355883839,"gmtModify":1633355985746,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] [财迷] [财迷] ","listText":"[财迷] [财迷] [财迷] ","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820344033","repostId":"1139003361","repostType":4,"repost":{"id":"1139003361","pubTimestamp":1633342670,"share":"https://www.laohu8.com/m/news/1139003361?lang=&edition=full","pubTime":"2021-10-04 18:17","market":"us","language":"en","title":"Is This The End Of The World As We Know It?","url":"https://stock-news.laohu8.com/highlight/detail?id=1139003361","media":"seekingalpha","summary":"Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upo","content":"<p>Summary</p>\n<ul>\n <li>Too many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.</li>\n <li>The market has struck an important support region.</li>\n <li>As long as this support holds, I am looking next to the 4900-5000SPX region.</li>\n <li>This idea was discussed in more depth with members of my private investing community, The Market Pinball Wizard.</li>\n</ul>\n<p>I have to tell you that I get the biggest chuckle out of the comments I read from people on Seeking Alpha.</p>\n<p>Recently, I read yet another bearish article on the market, and I found a comment which I can appropriately summarize thusly:</p>\n<blockquote>\n <i>\"I love your articles. They are so well written, such great charts, such great analysis, but why has the crash not happened yet?\"</i>\n</blockquote>\n<p>Then, I saw the following response:</p>\n<blockquote>\n <i>\"The crash hasn't happened because the market is in denial. If it weren't for that, the analysis would be spot on. The market simply refuses to acknowledge reality. It really should talk to a psychologist.\"</i>\n</blockquote>\n<p>Folks, the point I am trying to make by highlighting these comments is that we cannot make the market bend to what we may believe to be “reality.” We need to look at the market objectively in order to make our assessments about the future direction of the market. Simply calling the market a name or thinking it has been displaced from reality will never help your investment account.</p>\n<p>Yet, most people have a bias as to what they think must happen in the market, and apply that bias to their investment account, with many even posting comments based upon that bias. The two comments above are perfect examples.</p>\n<p>The main problem is that many do not have the appropriate objective tools with which to ascertain market direction. Rather, many view the market fundamentals as providing the clues to market direction. But, unfortunately, that is not how the market works, and it has seriously led people astray, with so many fighting this rally off the March 2020 lows.</p>\n<p>I have explained this in past articles such as this one, but the main point is that sentiment is what drives the market and places the spin on how the public views any of the fundamentals. If the market is in a positive sentiment trend, then negative fundamentals will be ignored, and vice versa. We have all seen markets rally on bad news and wonder “how the heck is this possible?” I often post this picture from Jim Cramer’s show as the perfect example of when this happens:</p>\n<p>With our objective analysis, not only did we catch the bottom last year at 2200SPX, I even said before we bottomed that we will likely see a strong rally to at least the 4000SPX region, with my ideal target being the 6000SPX region. Now, if you remember the emotional environment at the time, I am sure you can understand why so many looked at me like I was crazy. But, it was clearly not the first call I have made that has elicited such a response. In fact, it was not even the 20th.</p>\n<p>I even saw one comment this past week that said:</p>\n<blockquote>\n <i>“Avi is right more often than I would like to admit.”</i>\n</blockquote>\n<p>The question I always ask is why do so many people fight what I am trying to teach? Well, there are a number of reasons.</p>\n<p>First, in order to accept what I am saying about the market, you have to unlearn all the things you have learned all these years about what drives the market.</p>\n<p>And, I can tell you that those that are able not only find it liberating, but also find it much more profitable:</p>\n<blockquote>\n <i>“Avi's service is a game changer! I started reading his public articles more than four years ago. I should have subscribed sooner. Through his service, I have learned to ignore the mass market miss-information. This has vastly improved my investing success. Put in the time to learn from the master. You won't believe the success you will achieve once you have gained this new perspective. Avi and his team are fantastic!”</i>\n</blockquote>\n<blockquote>\n <i>“I have heard and read about Avi Gilburt and The Market Pinball Wizard for several years prior to actually joining. Like others here I subscribed to several authors including Avi, and would read the public articles. At first, I like probably many others, was skeptical of the service and what was put forth . . . I had to \"unlearn what I had learned\", tune out the news and TV pundits and focus on purely the market. This was not easy as I usually thought the market was hooked at the hip of the economy in real time. Whether you are a novice investor and are just looking for \"macro\" ideas and guidance as to what's in front of you or a seasoned pro, this service, in my opinion, is invaluable! . . . This service is a investment game changer for sure!!”</i>\n</blockquote>\n<p>Second, it requires you to understand that the market is driven by emotion and not by logic. In order to do so, many have to give up viewing the market logically. Yet, most people cannot accept the market action unless they believe they know the reason as to why the market moved.</p>\n<p>What they don’t understand is that reasons are completely useless. They are only offered by the media and pundits after the fact to attempt to explain a move that already happened. And, there are many times they cannot even find a reason as to why a market move happened, which leads to some of the funniest headlines you will see, assuming you are paying attention.</p>\n<p>Consider what was written by Professor Hernan Cortes Douglas, former Luksic Scholar at Harvard University, former Deputy Research Administrator at the World Bank, and former Senior Economist at the IMF, regarding those engaged in “fundamental” analysis for predictive purposes regarding the stock market:</p>\n<blockquote>\n <i>The historical data say that they cannot succeed; financial markets never collapse when things look bad. In fact, quite the contrary is true. Before contractions begin, macroeconomic flows always look fine. That is why the vast majority of economists always proclaim the economy to be in excellent health just before it swoons. Despite these failures, indeed despite repeating almost precisely those failures, economists have continued to pore over the same macroeconomic fundamentals for clues to the future. If the conventional macroeconomic approach is useless even in retrospect, if it cannot explain or understand an outcome when we know what it is, has it a prayer of doing so when the goal is assessing the future?</i>\n</blockquote>\n<p>And, the exact opposite is true. Did not the economic world consider us in a recession during the entire rally from 2200 to 4000?</p>\n<p>As we came into 2021 (with the market starting the year out at 3750SPX), I outlined to those willing to listen that I was expecting at least a 20% rally, with at least the 4600SPX as my target for 2021. That means I was looking for a rally of at least 850 points. Thus far, we have clearly exceeded my 20% minimum rally expectation, and the market has rallied 800 points and come within 50 points of the 4600SPX target I set for this year.</p>\n<p>Many months ago I also noted that I think we can get a 200-300 point pullback from the 4440-4600SPX region before we are ready to rally through 4600SPX. And, as we can see now, the market is again obliging our expectations.</p>\n<p>The funny thing is that I actually got chided recently by another commenter that acknowledged that we are getting the 200-300 point pullback I was expecting, but faulted me for the market topping at 4550SPX and not 4600SPX. I just shook my head in amazement when I read that comment. I caught 800 of the 850 points I called for earlier this year, and even called for this 200-300 point decline. But, sadly, I was simply not perfect in his myopic view. The real truth is that I noted that the 200-300 point decline can begin from the 4440-4600SPX target zone. But, who cares about the truth. (smile)</p>\n<p>Again, it is just so hard for people to let go of what they believe about the market. Sadly, this is the nature of far too many market participants, as so many still fight what I am trying to outline and teach about the market. But, rest assured, I still think we have plenty of time to be able to get to that 4600SPX mark before the end of the year, and potentially even exceed it.</p>\n<p>For many months, I have been outlining a major market pivot to the members of my The Market Pinball Wizard analysis service between 4095-4270SPX. That is the major support in the market at this time. And, I noted earlier this year to our members that once the market exceeds that pivot, it will rally into the 4440-4600SPX region, and then come back to test that market pivot from above. As long as the market holds that support region, I am looking for a signal that we have begun our next rally to our next major target in the 4900-5000SPX region.</p>\n<p>At the end of the week this past week, the futures market struck the top of this support region at the equivalent of the 4270SPX on the nose, and Friday we experienced a very strong rally off that support. Yet, I need to see a 5-wave structure off the low to provide us with our initial signal that the rally to 4900+ has begun in earnest.</p>\n<p>If we do not see that 5-wave structure complete early in the coming week, and instead, we break down below 4320SPX, then it likely means that this current pullback has not yet completed, and we will likely drop towards the 4200-4220SPX region, and ultimately point us down towards the 4165SPX region.</p>\n<p>So, I believe the coming week will provide us clues as to whether we have hit our bottom at the top end of our support region, and have begun the next rally to 4900+, or if we have deeper to go into our support region before that next rally begins in earnest.</p>\n<p>Hey, who knows? I could always be wrong. But, when the two top trending articles on Seeking Alpha this weekend were about an impending bear market and the most dangerous market ever, well, the boat is starting to feel a bit weighty on one side. Have a good week all.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is This The End Of The World As We Know It?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs This The End Of The World As We Know It?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 18:17 GMT+8 <a href=https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.\nThe market has struck an important support region.\nAs long as this ...</p>\n\n<a href=\"https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4458221-sentiment-speaks-is-this-the-end-of-the-world-as-we-know-it","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1139003361","content_text":"Summary\n\nToo many investors retain a negative bias of the market because of news or fundamentals upon which they solely focus.\nThe market has struck an important support region.\nAs long as this support holds, I am looking next to the 4900-5000SPX region.\nThis idea was discussed in more depth with members of my private investing community, The Market Pinball Wizard.\n\nI have to tell you that I get the biggest chuckle out of the comments I read from people on Seeking Alpha.\nRecently, I read yet another bearish article on the market, and I found a comment which I can appropriately summarize thusly:\n\n\"I love your articles. They are so well written, such great charts, such great analysis, but why has the crash not happened yet?\"\n\nThen, I saw the following response:\n\n\"The crash hasn't happened because the market is in denial. If it weren't for that, the analysis would be spot on. The market simply refuses to acknowledge reality. It really should talk to a psychologist.\"\n\nFolks, the point I am trying to make by highlighting these comments is that we cannot make the market bend to what we may believe to be “reality.” We need to look at the market objectively in order to make our assessments about the future direction of the market. Simply calling the market a name or thinking it has been displaced from reality will never help your investment account.\nYet, most people have a bias as to what they think must happen in the market, and apply that bias to their investment account, with many even posting comments based upon that bias. The two comments above are perfect examples.\nThe main problem is that many do not have the appropriate objective tools with which to ascertain market direction. Rather, many view the market fundamentals as providing the clues to market direction. But, unfortunately, that is not how the market works, and it has seriously led people astray, with so many fighting this rally off the March 2020 lows.\nI have explained this in past articles such as this one, but the main point is that sentiment is what drives the market and places the spin on how the public views any of the fundamentals. If the market is in a positive sentiment trend, then negative fundamentals will be ignored, and vice versa. We have all seen markets rally on bad news and wonder “how the heck is this possible?” I often post this picture from Jim Cramer’s show as the perfect example of when this happens:\nWith our objective analysis, not only did we catch the bottom last year at 2200SPX, I even said before we bottomed that we will likely see a strong rally to at least the 4000SPX region, with my ideal target being the 6000SPX region. Now, if you remember the emotional environment at the time, I am sure you can understand why so many looked at me like I was crazy. But, it was clearly not the first call I have made that has elicited such a response. In fact, it was not even the 20th.\nI even saw one comment this past week that said:\n\n“Avi is right more often than I would like to admit.”\n\nThe question I always ask is why do so many people fight what I am trying to teach? Well, there are a number of reasons.\nFirst, in order to accept what I am saying about the market, you have to unlearn all the things you have learned all these years about what drives the market.\nAnd, I can tell you that those that are able not only find it liberating, but also find it much more profitable:\n\n“Avi's service is a game changer! I started reading his public articles more than four years ago. I should have subscribed sooner. Through his service, I have learned to ignore the mass market miss-information. This has vastly improved my investing success. Put in the time to learn from the master. You won't believe the success you will achieve once you have gained this new perspective. Avi and his team are fantastic!”\n\n\n“I have heard and read about Avi Gilburt and The Market Pinball Wizard for several years prior to actually joining. Like others here I subscribed to several authors including Avi, and would read the public articles. At first, I like probably many others, was skeptical of the service and what was put forth . . . I had to \"unlearn what I had learned\", tune out the news and TV pundits and focus on purely the market. This was not easy as I usually thought the market was hooked at the hip of the economy in real time. Whether you are a novice investor and are just looking for \"macro\" ideas and guidance as to what's in front of you or a seasoned pro, this service, in my opinion, is invaluable! . . . This service is a investment game changer for sure!!”\n\nSecond, it requires you to understand that the market is driven by emotion and not by logic. In order to do so, many have to give up viewing the market logically. Yet, most people cannot accept the market action unless they believe they know the reason as to why the market moved.\nWhat they don’t understand is that reasons are completely useless. They are only offered by the media and pundits after the fact to attempt to explain a move that already happened. And, there are many times they cannot even find a reason as to why a market move happened, which leads to some of the funniest headlines you will see, assuming you are paying attention.\nConsider what was written by Professor Hernan Cortes Douglas, former Luksic Scholar at Harvard University, former Deputy Research Administrator at the World Bank, and former Senior Economist at the IMF, regarding those engaged in “fundamental” analysis for predictive purposes regarding the stock market:\n\nThe historical data say that they cannot succeed; financial markets never collapse when things look bad. In fact, quite the contrary is true. Before contractions begin, macroeconomic flows always look fine. That is why the vast majority of economists always proclaim the economy to be in excellent health just before it swoons. Despite these failures, indeed despite repeating almost precisely those failures, economists have continued to pore over the same macroeconomic fundamentals for clues to the future. If the conventional macroeconomic approach is useless even in retrospect, if it cannot explain or understand an outcome when we know what it is, has it a prayer of doing so when the goal is assessing the future?\n\nAnd, the exact opposite is true. Did not the economic world consider us in a recession during the entire rally from 2200 to 4000?\nAs we came into 2021 (with the market starting the year out at 3750SPX), I outlined to those willing to listen that I was expecting at least a 20% rally, with at least the 4600SPX as my target for 2021. That means I was looking for a rally of at least 850 points. Thus far, we have clearly exceeded my 20% minimum rally expectation, and the market has rallied 800 points and come within 50 points of the 4600SPX target I set for this year.\nMany months ago I also noted that I think we can get a 200-300 point pullback from the 4440-4600SPX region before we are ready to rally through 4600SPX. And, as we can see now, the market is again obliging our expectations.\nThe funny thing is that I actually got chided recently by another commenter that acknowledged that we are getting the 200-300 point pullback I was expecting, but faulted me for the market topping at 4550SPX and not 4600SPX. I just shook my head in amazement when I read that comment. I caught 800 of the 850 points I called for earlier this year, and even called for this 200-300 point decline. But, sadly, I was simply not perfect in his myopic view. The real truth is that I noted that the 200-300 point decline can begin from the 4440-4600SPX target zone. But, who cares about the truth. (smile)\nAgain, it is just so hard for people to let go of what they believe about the market. Sadly, this is the nature of far too many market participants, as so many still fight what I am trying to outline and teach about the market. But, rest assured, I still think we have plenty of time to be able to get to that 4600SPX mark before the end of the year, and potentially even exceed it.\nFor many months, I have been outlining a major market pivot to the members of my The Market Pinball Wizard analysis service between 4095-4270SPX. That is the major support in the market at this time. And, I noted earlier this year to our members that once the market exceeds that pivot, it will rally into the 4440-4600SPX region, and then come back to test that market pivot from above. As long as the market holds that support region, I am looking for a signal that we have begun our next rally to our next major target in the 4900-5000SPX region.\nAt the end of the week this past week, the futures market struck the top of this support region at the equivalent of the 4270SPX on the nose, and Friday we experienced a very strong rally off that support. Yet, I need to see a 5-wave structure off the low to provide us with our initial signal that the rally to 4900+ has begun in earnest.\nIf we do not see that 5-wave structure complete early in the coming week, and instead, we break down below 4320SPX, then it likely means that this current pullback has not yet completed, and we will likely drop towards the 4200-4220SPX region, and ultimately point us down towards the 4165SPX region.\nSo, I believe the coming week will provide us clues as to whether we have hit our bottom at the top end of our support region, and have begun the next rally to 4900+, or if we have deeper to go into our support region before that next rally begins in earnest.\nHey, who knows? I could always be wrong. But, when the two top trending articles on Seeking Alpha this weekend were about an impending bear market and the most dangerous market ever, well, the boat is starting to feel a bit weighty on one side. Have a good week all.","news_type":1},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886005693,"gmtCreate":1631535569712,"gmtModify":1631890655211,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[财迷] [财迷] [财迷] ","listText":"[财迷] [财迷] [财迷] ","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886005693","repostId":"1129341543","repostType":4,"repost":{"id":"1129341543","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631534652,"share":"https://www.laohu8.com/m/news/1129341543?lang=&edition=full","pubTime":"2021-09-13 20:04","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129341543","media":"Tiger Newspress","summary":"U.S. stock index futures rose on Monday after the S&P 500 logged its worst week in more than two mon","content":"<p>U.S. stock index futures rose on Monday after the S&P 500 logged its worst week in more than two months, with investors keeping a close eye on inflation as well as monetary and tax policies.</p>\n<p>S&P 500 E-minis were up 23.25 points, or 0.52% at 08:00 am ET. Dow E-minis were up 183 points, or 0.53%, while Nasdaq 100 E-minis were up 75 points, or 0.49%.</p>\n<p><img src=\"https://static.tigerbbs.com/2d51dd22d532e1b98f0ecae05c1f7a3e\" tg-width=\"1080\" tg-height=\"416\" width=\"100%\" height=\"auto\"></p>\n<p>Apple Inc rose 0.9% in premarket trading after a mixed court ruling in Epic Games’ antitrust case against the iPhone maker knocked nearly $90 billion off its market value on Friday.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Virgin Galactic(SPCE)</b> – Virgin Galactic is delaying its first commercial research space mission after a third-party supplier warned of a potential defect in a component of the flight control system. Virgin Galactic shares slid 3.3% in the premarket.</p>\n<p><b>Dell Technologies(DELL) </b>– Dell added 1.9% in premarket action after Goldman Sachs added the computer maker’s stock to its “Conviction Buy” list. Goldman cited strong cash flow generation and debt paydown plans, among other factors.</p>\n<p><b>TransUnion(TRU)</b> – TransUnion announced a deal to buy closely held information services company Neustar for $3.1 billion in cash. The credit reporting agency expects the deal to close during the fourth quarter.</p>\n<p><b>Viacom(VIAC) </b>– Viacom is planning a revamp of its Paramount Pictures unit, according to people familiar with the matter who spoke to The Wall Street Journal. The revamp, which would separate the TV and film operations, could be announced as soon as today. Viacom rose 1% in the premarket.</p>\n<p><b>Kansas City Southern(KSU)</b> – Kansas City Southern said the latest takeover bid from Canadian Pacific Railway(CP) is superior to the one it previously agreed to with Canadian National Railway(CNI). Canadian National now has five days to improve its offer, should it choose to do so. Canadian Pacific rallied 0.9% in premarket trading.</p>\n<p><b>Walt Disney(DIS)</b> – Disney will show the remainder of its 2021 movie releases exclusively in theaters, rather than making them simultaneously available on its Disney+ streaming service. Disney’s “Shang-Chi and the Legend of the 10 Rings” topped the weekend box office once again following its record Labor Day weekend performance, with that movie showing exclusively in theaters.</p>\n<p><b>Alibaba(BABA)</b> – Alibaba fell 1.7% in premarket action.</p>\n<p><b>Apple(AAPL)</b> – Epic Games will appeal Friday’s ruling that Apple’s app store was not an illegal monopoly. Epic did win a partial victory in the case, with the judge ruling that Apple must allow developers to include external payment links.</p>\n<p><b>Carlyle Group(CG)</b> – Carlyle is considering a $6 billion sale or initial public offering for packaging company Novolex, according to a Bloomberg report. The private-equity firm bought Novolex for an undisclosed amount in November 2016.</p>\n<p><b>MGM Resorts(MGM)</b> – MGM rose 1.5% in the premarket after Bernstein upgraded the resort operator’s stock to “outperform” from “market perform,” citing its strong presence in the gaming and sports betting industry as well as moves to divest the company’s real estate portfolio.</p>\n<p><b>Pfizer(PFE) </b>– Pfizer’s Covid-19 vaccine – developed in conjunction with German partner BioNTech(BNTX) – could be authorized for use in children aged 5-11 as soon as next month, according to two sources familiar with the situation who spoke to Reuters. Pfizer is expected to have enough study data by then to submit an application for emergency use authorization to the Food and Drug Administration. BioNTech added 1.1% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-13 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures rose on Monday after the S&P 500 logged its worst week in more than two months, with investors keeping a close eye on inflation as well as monetary and tax policies.</p>\n<p>S&P 500 E-minis were up 23.25 points, or 0.52% at 08:00 am ET. Dow E-minis were up 183 points, or 0.53%, while Nasdaq 100 E-minis were up 75 points, or 0.49%.</p>\n<p><img src=\"https://static.tigerbbs.com/2d51dd22d532e1b98f0ecae05c1f7a3e\" tg-width=\"1080\" tg-height=\"416\" width=\"100%\" height=\"auto\"></p>\n<p>Apple Inc rose 0.9% in premarket trading after a mixed court ruling in Epic Games’ antitrust case against the iPhone maker knocked nearly $90 billion off its market value on Friday.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Virgin Galactic(SPCE)</b> – Virgin Galactic is delaying its first commercial research space mission after a third-party supplier warned of a potential defect in a component of the flight control system. Virgin Galactic shares slid 3.3% in the premarket.</p>\n<p><b>Dell Technologies(DELL) </b>– Dell added 1.9% in premarket action after Goldman Sachs added the computer maker’s stock to its “Conviction Buy” list. Goldman cited strong cash flow generation and debt paydown plans, among other factors.</p>\n<p><b>TransUnion(TRU)</b> – TransUnion announced a deal to buy closely held information services company Neustar for $3.1 billion in cash. The credit reporting agency expects the deal to close during the fourth quarter.</p>\n<p><b>Viacom(VIAC) </b>– Viacom is planning a revamp of its Paramount Pictures unit, according to people familiar with the matter who spoke to The Wall Street Journal. The revamp, which would separate the TV and film operations, could be announced as soon as today. Viacom rose 1% in the premarket.</p>\n<p><b>Kansas City Southern(KSU)</b> – Kansas City Southern said the latest takeover bid from Canadian Pacific Railway(CP) is superior to the one it previously agreed to with Canadian National Railway(CNI). Canadian National now has five days to improve its offer, should it choose to do so. Canadian Pacific rallied 0.9% in premarket trading.</p>\n<p><b>Walt Disney(DIS)</b> – Disney will show the remainder of its 2021 movie releases exclusively in theaters, rather than making them simultaneously available on its Disney+ streaming service. Disney’s “Shang-Chi and the Legend of the 10 Rings” topped the weekend box office once again following its record Labor Day weekend performance, with that movie showing exclusively in theaters.</p>\n<p><b>Alibaba(BABA)</b> – Alibaba fell 1.7% in premarket action.</p>\n<p><b>Apple(AAPL)</b> – Epic Games will appeal Friday’s ruling that Apple’s app store was not an illegal monopoly. Epic did win a partial victory in the case, with the judge ruling that Apple must allow developers to include external payment links.</p>\n<p><b>Carlyle Group(CG)</b> – Carlyle is considering a $6 billion sale or initial public offering for packaging company Novolex, according to a Bloomberg report. The private-equity firm bought Novolex for an undisclosed amount in November 2016.</p>\n<p><b>MGM Resorts(MGM)</b> – MGM rose 1.5% in the premarket after Bernstein upgraded the resort operator’s stock to “outperform” from “market perform,” citing its strong presence in the gaming and sports betting industry as well as moves to divest the company’s real estate portfolio.</p>\n<p><b>Pfizer(PFE) </b>– Pfizer’s Covid-19 vaccine – developed in conjunction with German partner BioNTech(BNTX) – could be authorized for use in children aged 5-11 as soon as next month, according to two sources familiar with the situation who spoke to Reuters. Pfizer is expected to have enough study data by then to submit an application for emergency use authorization to the Food and Drug Administration. BioNTech added 1.1% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DELL":"戴尔",".IXIC":"NASDAQ Composite","MGM":"美高梅","PFE":"辉瑞","BNTX":"BioNTech SE","KSU":"堪萨斯南方铁路","DIS":"迪士尼","AAPL":"苹果","CG":"凯雷","SPCE":"维珍银河",".SPX":"S&P 500 Index","TRU":"TransUnion","BABA":"阿里巴巴",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129341543","content_text":"U.S. stock index futures rose on Monday after the S&P 500 logged its worst week in more than two months, with investors keeping a close eye on inflation as well as monetary and tax policies.\nS&P 500 E-minis were up 23.25 points, or 0.52% at 08:00 am ET. Dow E-minis were up 183 points, or 0.53%, while Nasdaq 100 E-minis were up 75 points, or 0.49%.\n\nApple Inc rose 0.9% in premarket trading after a mixed court ruling in Epic Games’ antitrust case against the iPhone maker knocked nearly $90 billion off its market value on Friday.\nStocks making the biggest moves in the premarket:\nVirgin Galactic(SPCE) – Virgin Galactic is delaying its first commercial research space mission after a third-party supplier warned of a potential defect in a component of the flight control system. Virgin Galactic shares slid 3.3% in the premarket.\nDell Technologies(DELL) – Dell added 1.9% in premarket action after Goldman Sachs added the computer maker’s stock to its “Conviction Buy” list. Goldman cited strong cash flow generation and debt paydown plans, among other factors.\nTransUnion(TRU) – TransUnion announced a deal to buy closely held information services company Neustar for $3.1 billion in cash. The credit reporting agency expects the deal to close during the fourth quarter.\nViacom(VIAC) – Viacom is planning a revamp of its Paramount Pictures unit, according to people familiar with the matter who spoke to The Wall Street Journal. The revamp, which would separate the TV and film operations, could be announced as soon as today. Viacom rose 1% in the premarket.\nKansas City Southern(KSU) – Kansas City Southern said the latest takeover bid from Canadian Pacific Railway(CP) is superior to the one it previously agreed to with Canadian National Railway(CNI). Canadian National now has five days to improve its offer, should it choose to do so. Canadian Pacific rallied 0.9% in premarket trading.\nWalt Disney(DIS) – Disney will show the remainder of its 2021 movie releases exclusively in theaters, rather than making them simultaneously available on its Disney+ streaming service. Disney’s “Shang-Chi and the Legend of the 10 Rings” topped the weekend box office once again following its record Labor Day weekend performance, with that movie showing exclusively in theaters.\nAlibaba(BABA) – Alibaba fell 1.7% in premarket action.\nApple(AAPL) – Epic Games will appeal Friday’s ruling that Apple’s app store was not an illegal monopoly. Epic did win a partial victory in the case, with the judge ruling that Apple must allow developers to include external payment links.\nCarlyle Group(CG) – Carlyle is considering a $6 billion sale or initial public offering for packaging company Novolex, according to a Bloomberg report. The private-equity firm bought Novolex for an undisclosed amount in November 2016.\nMGM Resorts(MGM) – MGM rose 1.5% in the premarket after Bernstein upgraded the resort operator’s stock to “outperform” from “market perform,” citing its strong presence in the gaming and sports betting industry as well as moves to divest the company’s real estate portfolio.\nPfizer(PFE) – Pfizer’s Covid-19 vaccine – developed in conjunction with German partner BioNTech(BNTX) – could be authorized for use in children aged 5-11 as soon as next month, according to two sources familiar with the situation who spoke to Reuters. Pfizer is expected to have enough study data by then to submit an application for emergency use authorization to the Food and Drug Administration. BioNTech added 1.1% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":833016613,"gmtCreate":1629188980932,"gmtModify":1631893057089,"author":{"id":"4089370506564720","authorId":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"[真香] [真香] ","listText":"[真香] [真香] ","text":"[真香] [真香]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/833016613","repostId":"1192890684","repostType":2,"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
